Calculating a per sample CD8 TEMRA and Macro CXCL10 enrichment score in transcriptomic data of 311 pre-treatment tumour biopsies of aHCC patients treated with atezo/bev (n = 253) versus sorafenib (n = 58), we found that high CD8 TEMRA and Macro CXCL10 enrichment scores were associated with significantly longer PFS in atezo/bev-treated patients (Fig. 7atop), but not in sorafenib-treated patients (Fig. 7abottom). The gene discussed is CD8A; the disease is neoplasm.